Compare Novartis AG (NVS) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs AT&T Inc. — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while AT&T Inc. trades at $23.27 (market cap $167.68B). The key difference: Novartis AG is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (4.54%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and AT&T Inc. for 118 Days on average.
| NVS | T | |
|---|---|---|
Market Cap | $274.00B | $167.68B |
Volume | 1,852,137 | 27,788,850 |
Sector | Health | Media |
52-Week High | $168.62 | $29.10 |
52-Week Low | $121.80 | $20.49 |
Typical Hold Time | 82 Days | 118 Days |
Enterprise Value | $315.32B | $313.00B |
Dividend Yield | 3.31% | 4.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
AT&T (T) trades at $24.885, up 1.88% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 8.08 and net income margin of 16.94%. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while cash flow improved to $15.12B in 2025.
The stock offers value with a 4%+ dividend yield and analyst consensus price target of $27.61, but faces risks from high debt and competitive pressures. Upside depends on execution in fiber and wireless, while sentiment is mixed amid dividend sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
